Search Results
Jan 12, 2026, 14:57 ET Adimab Reports Strong Partnering Year for 2025
engineering necessary for certain partner-desired formats.T Cell Engagers: Adimab has a highly characterized suite of functional and diverse CD3 and CD28 antibodies (both IgG and VHH binders) to generate bi- and multispecific T cell engagers. Adimab has partnered this program non-exclusively with
More news about: Adimab, LLC
Jan 12, 2026, 10:30 ET Al in Clinical Workflow Market worth $11.08 billion by 2030 | MarketsandMarkets™
America is projected to lead the market due to its mature IT infrastructure and a large adoption base for EHR systems, early adoption rates for AI-enabled CD solutions, and a strong presence of large health technology companies in the market. Favorable payment structures, the shift to value-based care, and
More news about: MarketsandMarkets
Jan 12, 2026, 08:00 ET Minaris and Genetix Biotherapeutics Expand Manufacturing Partnership to Support Commercial Supply for LYFGENIA™ (lovotibeglogene autotemcel)
has been achieved. If neutrophil engraftment failure occurs in a patient treated with LYFGENIA, provide rescue treatment with the back-up collection of CD34+ cells.Insertional OncogenesisThere is a potential risk of lentiviral vector-mediated insertional oncogenesis after treatment
More news about: Minaris Advanced Therapies
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).For the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL), not otherwise
More news about: Karyopharm Therapeutics Inc.
Jan 09, 2026, 16:00 ET Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
Data presented at ASCO GI 2026 show spevatamig, an anti-CLDN18.2/CD47 bsAb, in combination with chemotherapy, has the potential to be an effective first-line (1L) treatment in patients with CLDN18.2 positive metastatic
More news about: Phanes Therapeutics, Inc.
Jan 08, 2026, 16:15 ET Sealed Air to Announce Fourth Quarter and Full Year 2025 Results
www.sealedair.com/investors.Given the pending acquisition by CD&R, Sealed Air will not be hosting a conference call this quarter or providing 2026 guidance.About Sealed AirSealed Air Corporation
More news about: Sealed Air
Jan 08, 2026, 16:05 ET ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Jan 08, 2026, 15:48 ET Osprey Real Estate Capital and Bruin Capital Partners Close 13-Acre Retail Site at I-11 and Kyle Canyon Road in the Sunstone Master Plan in 56 Days
The property was acquired by CD Kyle Canyon, LLC, a joint venture between Osprey Real Estate Capital and Bruin Capital Partners. The seller was Northland, LLC.The site is strategically
More news about: Osprey Real Estate Capital
Jan 08, 2026, 08:28 ET Disrupting VC Blind Spots: Chris Dolezalek on Using Data to Find the Next Unicorns
has led product and engineering organizations through some of the most challenging and transformative moments in tech. His expertise includes DevOps, CI/CD, SRE, platform reliability, developer tooling, and infrastructure engineering, achieving 7–9s uptime at scale. From architecting the early foundation
More news about: Disruption Interruption
Jan 08, 2026, 08:00 ET Invicti Security Awarded Best Place to Work Again
application frontends and APIs. With its best-of-breed dynamic application security testing (DAST) acting as the fact-checker, Invicti integrates into CI/CD pipelines to deliver proof-based results supported by AI-powered prioritization and remediation. Built on more than 20 years of DAST innovation through
More news about: Invicti Security
Jan 08, 2026, 07:30 ET KAHR Bio Announces Strong Topline Phase 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in Colorectal Cancer
first-in-class, bispecific CD47×4-1BB targeting, next-generation T-cell engager. DSP107 utilizes tumor-expressed CD47 as an anchor, selectively binding CD47 on cancer cells while sparing red blood cells, thereby overcoming the safety challenges previously seen with other CD47-directed agents. Once bound,
More news about: KAHR Medical
Jan 08, 2026, 07:15 ET ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Jan 08, 2026, 03:00 ET AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
diseases. ABO21009 is effective through a multi-pronged mechanism of action, selectively depleting CD45RC-positive cells that are actively sustaining the autoimmune response in Rheumatoid Arthritis. These CD45RC-positive cells are present in the T-, B-, and NK-cell compartments of the adaptive immune system.
More news about: AbolerIS Pharma
Jan 07, 2026, 10:19 ET What CDs Gained the Most Traction Last Year? CD Valet's 2025 Analysis Reveals Interest in Short-Term CDs and a Yield Curve Beginning to Flatten
customers."About CD Valet CD Valet is a CD marketplace that features verified CD rates from federally insured banks and credit unions nationwide. With tens of thousands of CD offers tracked across the country, CD Valet gives savers a clear view of top rates and helps them explore higher-yield CD options
More news about: CD Valet
Jan 07, 2026, 08:33 ET Korea University Researchers Discover That Cholesterol-lowering Drug Can Overcome Chemotherapy Resistance in Triple-Negative Breast Cancer
pathways. The drug effectively eliminated cancer stem-like cell populations, reduced ALDH1 activity, suppressed the CD44high/CD24low and CD24high/CD49high subpopulations, and sharply inhibited mammosphere formation. These effects extended to patient-derived TNBC organoids,
More news about: Korea University College of Medicine
Jan 06, 2026, 22:32 ET Une IA en quête de vérité crée le plus grand portail de connaissances encyclopédiques au monde - 6 000 fois plus grand que Wikipédia
Les encyclopédies ont parcouru un long chemin, depuis les éditions imprimées des années 1800 et les CD ROM des années 1990, jusqu'à la Wikipédia en ligne d'aujourd'hui, éditée par la communauté. Alors, quelle est la prochaine étape ?Botipedia, propulsé
More news about: INSEAD
Jan 06, 2026, 13:27 ET Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS
oligonucleotide therapeutics targeting microglial dysfunction and neuroinflammation across ALS, FTD, AD and related neurodegenerative diseases. Together with its CD33 program, the company is building a portfolio of precision RNA medicines designed to restore microglial homeostasis and slow neurodegeneration by modulating
More news about: Aperture Therapeutics
Jan 06, 2026, 10:44 ET Boulder iQ Participates in RESI JPM, MD&M West
Boulder Sterilization, provides both quick-turn ethylene oxide (EO) and chlorine dioxide (CD) sterilization services for medical devices. The newly opened
More news about: Boulder iQ
Jan 06, 2026, 10:00 ET First Patients Enrolled in Groundbreaking Brain Cancer Study at Nationally Recognized Academic Medical Center
recurrent glioblastoma, and the other - testing a combination therapy that delivers two experimental drugs, D2C7-IT in combination with an Fc engineered Anti-CD40 Monoclonal Antibody, directly into the tumor and surrounding tissue to target cancer cells more precisely.D2C7-IT is an investigational immunotoxin
More news about: Exvade Bioscience, Inc.
Jan 06, 2026, 09:05 ET Synopsys Showcases Vision For AI-Driven, Software-Defined Automotive Engineering at CES 2026
implementation to jump-start development. This solution supports scalable virtual development with multi-ECU, multi-vendor integration as well as CI/CD pipelines from concept through silicon for continuous updates throughout the vehicle lifecycle. Learn more
More news about: Synopsys, Inc.
Jan 06, 2026, 07:00 ET ActiveState Survey Finds Container Security Gaps Expose Enterprises to Breach and Audit Risks
provides a curated catalog of more than 40 million secure open source components and container images that can be consumed via artifact repository, CI/CD, IDE, or directly from ActiveState. ActiveState continuously monitors and updates the open source components to help keep companies vulnerability free.
More news about: ActiveState
Jan 06, 2026, 06:30 ET VIAVI Announces Industry's First Long-Range Hollow Core Fiber Bidirectional Testing and Certification Solution
leading hyperscalers.Compared to single mode fiber, hollow core fiber enables up to 30% lower latency, up to 70% reduced Chromatic Dispersion (CD), up to 65% lower attenuation and reduced signal distortion. This enables faster data transmission over increased distances without the need for amplification
More news about: VIAVI Solutions
Jan 05, 2026, 18:20 ET Acer Unleashes the Predator XB273U F6 Gaming Monitor, a 1000 Hz Powerhouse Pushing Performance Boundaries
2,000:1 (Native)Brightness (cd/m2)350 nits
More news about: Acer
Jan 05, 2026, 06:30 ET MulticoreWare Demonstrates Real-Time Cloud-to-Car AI Workflow with Qualcomm AI HUB and QCR100 Instance at CES 2026
transition from FP32 to quantized INT8/INT16 models.Scalable Cloud Workflow: On-demand access to QCR100 instances for global validation and CI/CD pipelines without on-premises hardware constraints.Unified Development & Validation Architecture: Compatibility between QCR100 cloud
More news about: MulticoreWare Inc.
Jan 02, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA